Factors in Selecting First-Line Therapy for Patients With Advanced RCC

Video

Comprehensive insight on the factors that help determine optimal first-line therapy for a patient presenting with advanced renal cell carcinoma.

Recent Videos
Given resource scarcity, developing practice strategies for resource-constrained settings would require aid from commercial and government stakeholders.
Large international meetings may facilitate conversations regarding disparities of care outside of high-income countries.
Observing changes in the tumor microenvironment before and after a biopsy may elucidate how kidney cancer cells interact with immune cells.
Various kidney cancer trials have combined agents such as A2a receptor inhibitors with immunotherapy backbones to potentially improve treatment outcomes.
Related Content
Data from the phase 3 ZIRCON study support the biologics license application for TLX250-CDx in clear cell renal cell carcinoma imaging.

FDA Grants Priority Review to TLX250-CDx in Clear Cell RCC Imaging

Russ Conroy
February 26th 2025
Article

Data from the phase 3 ZIRCON study support the biologics license application for TLX250-CDx in clear cell renal cell carcinoma imaging.

Traversing the Complexities of Non-Clear Cell Renal Cell Carcinoma

Traversing the Complexities of Non-Clear Cell Renal Cell Carcinoma

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Stephanie A. Berg, DO
March 7th 2025
Podcast

A brief overview of the current RCC landscape was provided in the most recent Oncology Decoded podcast.

LITESPARK-004 and LITESPARK-005 trial results support the approval of belzutifan in patients with associated localized or advanced clear cell RCC.

Belzutifan Receives European Approval in Localized/Advanced RCC Indications

Roman Fabbricatore
February 18th 2025
Article

LITESPARK-004 and LITESPARK-005 trial results support the approval of belzutifan in patients with associated localized or advanced clear cell RCC.

Expanding and Advancing the Future of Renal Cell Carcinoma Treatment

Expanding and Advancing the Future of Renal Cell Carcinoma Treatment

Eric Jonasch, MD
February 3rd 2025
Podcast

Eric Jonasch, MD, believes that the Kidney Cancer Research Consortium may broaden their reach to provide care to many different groups of patients.

Cabozantinib Combo Yields Sustained PFS at Follow-Up in Advanced RCC

Cabozantinib Combo Yields Sustained PFS at Follow-Up in Advanced RCC

Ariana Pelosci
February 15th 2025
Article

Efficacy results remained consistent with previous reports in the cabozantinib, nivolumab, and ipilimumab arm for patients with advanced renal cell carcinoma.

Nivolumab/Cabozantinib Demonstrates Long-Term Efficacy in Advanced RCC

Nivolumab/Cabozantinib Demonstrates Long-Term Efficacy in Advanced RCC

Tim Cortese
February 15th 2025
Article

Nivolumab plus cabozantinib yielded a median PFS of 16.4 months compared with 8.3 months from sunitinib alone in the first-line treatment of patients with advanced RCC.